<DOC>
	<DOCNO>NCT01647659</DOCNO>
	<brief_summary>The purpose open-label , randomize , 2-treatment , 2-period crossover study incomplete washout evaluate relative bioavailability 2mg GSK1120212 pediatric oral solution formulation comparison 2mg GSK1120212 tablet formulation , investigate safety tolerability single dose GSK1120212 pediatric oral solution formulation compare single dose GSK1120212 tablet formulation , investigate palatability GSK1120212 pediatric oral solution formulation . Subjects assign one two possible treatment sequence accord randomization code provide site GSK : single dose 2mg GSK1120212 pediatric oral solution formulation single dose 2mg GSK1120212 tablet formulation , single dose 2mg GSK1120212 tablet formulation , single dose 2mg GSK1120212 pediatric oral solution formulation . Administration GSK1120212 either sequence follow 7 day serial blood sample pharmacokinetic analysis plasma GSK1120212 . Safety assessment , include assessment adverse event , clinical laboratory value ( hematology , clinical chemistry urinalysis ) vital sign , make throughout study . After complete pharmacokinetic assessment two period , eligible subject may transition MEK114375 , open-label rollover study GSK1120212 .</brief_summary>
	<brief_title>Relative Bioavailibilty Pediatric Powder Suspension ( PfOS ) Formulation</brief_title>
	<detailed_description>The purpose open-label , randomize , 2-treatment , 2-period crossover study incomplete washout evaluate relative bioavailability 2mg GSK1120212 pediatric oral solution formulation comparison 2mg GSK1120212 tablet formulation , investigate safety tolerability single dose GSK1120212 pediatric oral solution formulation compare single dose GSK1120212 tablet formulation , investigate palatability GSK1120212 pediatric oral solution formulation . Subjects assign one two possible treatment sequence accord randomization code provide site GSK : single dose 2mg GSK1120212 pediatric oral solution formulation single dose 2mg GSK1120212 tablet formulation , single dose 2mg GSK1120212 tablet formulation , single dose 2mg GSK1120212 pediatric oral solution formulation . Administration GSK1120212 either sequence follow 7 day serial blood sample pharmacokinetic analysis plasma GSK1120212 . Safety assessment , include assessment adverse event , clinical laboratory value ( hematology , clinical chemistry urinalysis ) vital sign , make throughout study . After complete pharmacokinetic assessment two period , eligible subject may transition MEK114375 , open-label rollover study GSK1120212 .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<criteria>Male female , 18 year age old , time signing informed consent . Capable give write informed consent , include compliance requirement restriction list consent form . Able swallow retain oral medication . Histologically cytologicallyconfirmed diagnosis solid tumor malignancy responsive standard therapy ; approve curative therapy ; subject refuse standard therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate baseline organ function , define : absolute neutrophil count &gt; = 1.2X10^9/L ; hemoglobin &gt; =9g/dL ; platelet &gt; =75X10^9/L ; prothrombin time ( PT ) , international normalize ratio ( INR ) partial thromboplastin time ( PTT ) &lt; =1.5 X upper limit normal ( ULN ) ; total bilirubin &lt; =1.5 X ULN ; alanine aminotransferase &lt; =2.5 X ULN ; creatinine &lt; =1.5 X ULN OR calculate creatinine clearance 24hour urine creatinine clearance &gt; = 50mL/min ; leave ventricular ejection fraction ( LVEF ) &gt; = low limit normal ( LLN ) ; systolic blood pressure &lt; 140mm Hg Women childbearing potential must negative serum pregnancy test within 14 day first dose investigational product administration agree use effective contraception , define protocol , study 6 week follow last dose investigational product . Male subject female partner childbearing potential must agree use one contraception method list protocol . This criterion must follow time first dose study medication 16 week last dose GSK1120212 . Exclusion criterion Currently receive cancer therapy ( e.g. , chemotherapy delay toxicity , extensive radiation therapy , immunotherapy , biologic therapy , major surgery ) within 3 week prior randomization ; chemotherapy regimens without delayed toxicity within 2 week prior randomization ; use investigational anticancer drug within 4 week prior randomization . Unresolved Grade 2 great toxicity ( base NCICTCAE , version 4.0 , 2009 ) previous anticancer therapy except Grade 2 decrease haemoglobin level alopecia . Preexisting peripheral neuropathy &gt; = Grade 2 . Has participate clinical trial receive investigational product within 30 day , 5 halflives twice duration biological effect investigational product , whichever longer , prior first dose investigational product study . Has participate clinical trial result make donation blood blood product excess 500mL within 56 day first dose investigational product study . Has presence active GI disease condition ( e.g. , gastrectomy , bariatric surgery , small large bowel resection , cholecystectomy ) may interfere significantly absorption drug . Any serious and/or unstable preexist medical ( aside malignancy exception ) , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent compliance study procedure , opinion investigator GSK medical monitor . History interstitial lung disease pneumonitis . History current evidence / risk retinal vein occlusion ( RVO ) central serous retinopathy ( CSR ) , include history RVO CSR , predispose factor RVO CSR ( e.g. , uncontrolled glaucoma ocular hypertension , uncontrolled systemic disease ( ) hypertension , diabetes mellitus , history hyperviscosity hypercoagulability syndrome ) ; visible retinal pathology assess ophthalmic exam consider risk factor RVO CSR evidence new optic disc cupping , evidence new visual field defect , intraocular pressure &gt; 21mm Hg . Has symptomatic untreated leptomeningeal brain metastasis spinal cord compression ; NOTE : Subjects previously treat condition stable central nervous system ( CNS ) disease ( verified consecutive imaging study ) &gt; 3 month , asymptomatic currently take corticosteroid , stable dose corticosteroid least 1 month prior Day 1 study permit . Subjects permit receive enzymeinducing antiepileptic drug ( EIAEDs ) . QTcB QTcF &gt; =480msec . Subject history evidence cardiovascular risk , include follow : history evidence current clinically significant uncontrolled arrhythmia . Exception : subject control atrial fibrillation &gt; 30days prior randomization eligible OR history acute coronary syndrome , include myocardial infarction unstable angina , coronary angioplasty , stenting , within 6months prior randomization . History evidence current &gt; =Class II congestive heart failure define New York Heart Association ( NYHA ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>MEK inhibitor GSK1120212</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>powder oral solution</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>pediatric formulation</keyword>
</DOC>